North America's Cardiovascular Drugs Market To Shrink 5% 2013-21

LONDON, GREATER LONDON , UK, June 21, 2018 /EINPresswire.com/ -- The North American market for drugs to treat heart disease fell by 2.9% year on year from 2013 to 2017 and although growth has picked up to 1.7% that still means that by 2021 it will be 5% smaller than it was in 2013. Up to 2017 it remained North America's largest market for drugs but by 2021 it will be overtaken by the markets for treating metabolic disorders such as diabetes and thyroidism. Drugs for treating arthritis, osteoporosis and other musculoskeletal conditions will also be neck and neck with the cardiovascular drugs in the North American market by 2021.

The cardiovascular drugs category covers drugs used to treat conditions that include heart attack or failure, strokes, coronary artery diseases, valvular diseases, peripheral venous diseases, pericarditis, endocarditis, cardiac tumors, arteriosclerosis, and lymphatic diseases. Major cardiovascular drugs include anti-hypertensive drugs such as calcium channel blockers and angiotensin II receptor antagonists, and hypolipidemic drugs such as fibric acid derivatives and bile acid binding resins.
In a region such as North America, which largely consists of the highly developed countries the USA and Canada, but also includes Mexico, drug spend is related to disease incidence and the development of new high-priced patented drugs as well as to population growth or GDP per capita. While heart attacks and strokes are still the leading cause of death in the USA, other conditions such as diabetes have increased in significance due to obesity and other lifestyle factors. Population aging and the availability of new treatments for arthritis and osteoporosis are boosting the market for musculoskeletal drugs.
The market for cardiovascular drugs is performing less well than any other major segment globally as well as in North America, having fallen year on year by 2% to 2017 and set to grow by only 2.2% annually to 2021. In Western Europe it is declining year on year throughout the eight-year period. Even in Asia Pacific it is achieving only a little over 5% a year, compared with over 8% for the pharma market as a whole in that region.

The global cardiovascular drugs market is fragmented - nearly 70% goes to players outside the top ten. The USA's Merck and Co with a nearly 8% market share, is the market leader, followed by French pharma company Sanofi with around 5%.

Where To Learn More
Read the Pharmaceutical Drugs Global Market Report 2018 from The Business Research Company for information on the following:
Markets covered: Markets for pharmaceuticals cardiovascular drugs, central nervous system drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorder drugs, musculoskeletal drugs, oncology drugs, ophthalmology drugs, respiratory drugs
Pharmaceutical Companies Covered: Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Gilead Sciences, Inc., Johnson & Johnson, GlaxoSmithKline Plc., Bayer AG, Teva Pharmaceuticals, Merck & Co.
Regions: North America, Asia Pacific, Western Europe, South America, Eastern Europe, Middle East, Africa.
Countries: USA, China, Japan, Germany, Brazil, France, Italy, UK, Australia, India, Spain, Russia.
Time Series: Five years historic (2013-17) and forecast (2017-21).
Data: Pharmaceutical market size and growth for 7 regions and 12 countries; pharmaceutical global regional and country market size and growth segmented by therapeutic area; market trends & strategies, market size by sub segment historic and forecast growth rate, by sub segment, competitive landscape, profiles of leading competitors, key mergers and acquisitions by each therapeutic segment, global, regional and country pharmaceutical per capita consumption and market size as a percentage of GDP 2013-21; leading competitors' financial performance 2013-21; pharmaceutical drugs market comparison with industry metrics.
Data Segmentations: Pharmaceutical drugs global market, global pharmaceutical drugs market by therapeutic area segments and sub segments; pharmaceutical drugs market by region and country and by therapeutic area segments; branded versus generic drugs markets by country; competitor drug sales and market shares by therapeutic area; global healthcare market historic and forecast size and growth; healthcare market regional and country size and growth; healthcare market competitive landscape.
Other Information: PESTEL analysis, drivers and restraints, customer and operational insights, pharmaceutical drugs market by country covering opportunities, industrial gas associations, investment and expansion plans, corporate tax structure and competitive landscape.
Sourcing and Referencing: Data and analysis throughout the report are sourced using end notes. Sources include primary as well as extensive secondary research.
Interested to know more? Here is a list of reports similar to “Pharmaceutical Drugs Global Market Report 2018”:
1. Cardiovascular Drugs Global Market Report 2018
2. Biologics Global Market Report 2018
3. Contract Research Organizations Global Market Report 2018
4. Organ-on-Chip Global Market Report 2018

Oliver Guirdham
The Business Research Company
+44 207 1930 708
email us here